DGAP-News: SYGNIS AG: SYGNIS AG successfully completes

DGAP-News: SYGNIS AG / Key word(s): Capital Increase SYGNIS AG: SYGNIS AG successfully completes Rights Offering 28.10.2013 / 09:09 --------------------------------------------------------------------- Press Release SYGNIS AG successfully completes Rights Offering and Private Placement Heidelberg, Germany, October 28, 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today announced that the Company has successfully completed its rights offering. The subscription price was EUR 2.65 per share. New shares that were not subscribed in the course of the rights offering by existing shareholders were offered to selected German and international institutional investors in a private placement at a purchase price equivalent to the subscription price. In the transaction 1,019,309 new shares against cash were subscribed. The Management Board, with the approval of the Supervisory Board, has resolved to increase the Company's share capital from EUR 9,364,258.00 to EUR 10,383,567.00 by issuing 1,019,309 new shares. The offering utilizes existing authorized capital created by resolution at the Annual General Meeting on August 28, 2013. The new shares carry full dividend rights as of January 1, 2013. 'We welcome our new shareholders and are very thankful for their trust in the new business direction of SYGNIS,' stated Pilar de la Huerta, CEO and CFO of SYGNIS AG. 'SYGNIS is a key player in the fast growing market of DNA amplification and sequencing. With the first commercial agreement around SYGNIS' core technology QualiPhi(R) with QIAGEN, the world leading provider of sample and assay technologies and a full pipeline with potential blockbuster products for next generation sequencing applications, SYGNIS is best positioned to benefit from the high growth rates we are seeing in gene-based personalized healthcare, molecular diagnostics and epigenetics. The transaction is in our view in the best interest of the Company and its shareholders as it provides the Company with the financial flexibility needed to further execute on its business plans and closes the gap to break-even expected in 2014.' SYGNIS plans to use the gross proceeds of EUR 2.7 million to finance its operating business and further growth. For further information please contact: <pre> SYGNIS AG Pilar de la Huerta CEO/CFO Tel: +34-918063089 Email: pdelahuerta@sygnis.es </pre> About SYGNIS AG: www.sygnis.com After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi(R) and is currently developing other products in the field of Next Generation Sequencing. ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### End of Corporate News --------------------------------------------------------------------- 28.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: SYGNIS AG Im Neuenheimer Feld 515 69120 Heidelberg Germany Phone: 06221 454-6 Fax: 06221 454-700 E-mail: contact@sygnis.de Internet: www.sygnis.de ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 236398 28.10.2013